Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00099491" target="_blank" >RIV/00216224:14110/17:00099491 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
Original language description
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine, Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
—
Continuities
O - Projekt operacniho programu
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů